ArticleJournal of hepatology2023
Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US.
Article in Journal of hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 80 citations in OpenAlex.
- The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis.Hepatology (Baltimore, Md.) · 2026Trial
- Urinary neutrophil gelatinase-associated lipocalin: a key biomarker for differentiating acute kidney injury and predicting short-term mortality in liver cirrhosis patients.Renal failure · 2026Observational
- Timing and trajectory of acute kidney injury predict mortality in alcohol-associated hepatitis: A multinational cohort study.Hepatology communications · 2026Article
- Terlipressin in paediatric hepatorenal syndrome-acute kidney injury (HRS-AKI).Pediatric nephrology (Berlin, Germany) · 2026Review
- Acute Kidney Injury in Patients With Cirrhosis Exposed to Iodinated Contrast: A Systematic Review and Meta-Analysis.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Clinical Significance of Acute Kidney Injury in Idiosyncratic Drug-Induced Liver Injury: A Multicentric Propensity Scores Matched Study.Clinical pharmacology and therapeutics · 2026Article
- Evaluation of Kidney Function in Cirrhosis: Methods and Pitfalls.Diagnostics (Basel, Switzerland) · 2026Review
- Machine learning outperforms serum creatinine for early risk stratification of hepatorenal syndrome: a prospective single-center validation.Hepatology international · 2026Article
- United States Experience With Terlipressin in Hepatorenal Syndrome: Response, Mortality, and Transplant Outcomes - Results From the HRS Harmony Consortium.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026Article
- Differentiating Hepatorenal Syndrome from Acute Tubular Necrosis in Patients with Decompensated Cirrhosis: Can Metabolomics or Proteomics Help?Digestive diseases and sciences · 2026Article
- Bridging Critically Ill Patients With Cirrhosis to Transplant With Renal Replacement Therapy: A Multicenter Cohort Study.Liver international : official journal of the International Association for the Study of the Liver · 2026Observational
- The global epidemiology of acute kidney injury: challenges and opportunities.Nature reviews. Nephrology · 2026Review
- Development and patterns of acute-on-chronic liver failure in patients with cirrhosis and acute kidney injury.JHEP reports : innovation in hepatology · 2026Article
- Real-World Indirect Treatment Comparison of Terlipressin vs Midodrine Plus Octreotide in Hepatorenal Syndrome-Acute Kidney Injury.Clinical and translational gastroenterology · 2026Article
- Treating Hepatorenal Syndrome in the Current Era.Journal of the American Society of Nephrology : JASN · 2026Review
- Applying Metabolomics and Aptamer-Based Proteomics to Determine Pathophysiologic Differences in Decompensated Cirrhosis Patients Hospitalized with Acute Kidney Injury.Digestive diseases and sciences · 2025Article
- A retrospective study on the use of albumin in the management of complications of decompensated cirrhosis from a major teaching hospital in Canada.Canadian liver journal · 2025Article
- Ambulatory Acute Kidney Injury in Patients With Cirrhosis Is Common and Burdensome.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025Article
- Acute kidney injury stage 1a increases mortality of patients with cirrhosis: a prospective multicenter cohort study.Hepatology international · 2025Article
- Challenges in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury: A US Chart Review of Treatment Patterns and Survival Outcomes.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors at 13 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsAcute kidney injury (AKI) in cirrhosis is common and associated with high morbidity, but the incidence rates of different etiologies of AKI are not well described in the US. We compared incidence rates, practice patterns, and outcomes across etiologies of AKI in cirrhosis.
methodsWe performed a retrospective cohort study of 11 hospital networks, including consecutive adult patients admitted with AKI and cirrhosis in 2019. The etiology of AKI was adjudicated based on pre-specified clinical definitions (prerenal/hypovolemic AKI, hepatorenal syndrome [HRS-AKI], acute tubular necrosis [ATN], other).
resultsA total of 2,063 patients were included (median age 62 [IQR 54-69] years, 38.3% female, median MELD-Na score 26 [19-31]). The most common etiology was prerenal AKI (44.3%), followed by ATN (30.4%) and HRS-AKI (12.1%); 6.0% had other AKI, and 7.2% could not be classified. In our cohort, 8.1% of patients received a liver transplant and 36.5% died by 90 days. The lowest rate of death was observed in patients with prerenal AKI (22.2%; p <0.001), while death rates were higher but not significantly different from each other in those with HRS-AKI and ATN (49.0% vs. 52.7%; p = 0.42). Using prerenal AKI as a reference, the adjusted subdistribution hazard ratio (sHR) for 90-day mortality was higher for HRS-AKI (sHR 2.78; 95% CI 2.18-3.54; p <0.001) and ATN (sHR 2.83; 95% CI 2.36-3.41; p <0.001). In adjusted analysis, higher AKI stage and lack of complete response to treatment were associated with an increased risk of 90-day mortality (p <0.001 for all).
conclusionAKI is a severe complication of cirrhosis. HRS-AKI is uncommon and is associated with similar outcomes to ATN. The etiology of AKI, AKI stage/severity, and non-response to treatment were associated with mortality. Further optimization of vasoconstrictors for HRS-AKI and supportive therapies for ATN are needed. IMPACT AND IMPLICATIONS: Acute kidney injury (AKI) in cirrhosis carries high morbidity, and management is determined by the etiology of injury. However, a large and well-adjudicated multicenter database from US centers that uses updated AKI definitions is lacking. Our findings demonstrate that acute tubular necrosis and hepatorenal syndrome have similar outcomes (∼50% mortality at 90 days), though hepatorenal syndrome is uncommon (12% of all AKI cases). These findings represent practice patterns at US transplant/tertiary centers and can be used as a baseline, presenting the situation prior to the adoption of terlipressin in the US.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.